Completed
PHASE1
INTERVENTIONAL
NCT03062618
A Study of PRCL-02 in Healthy Volunteers and Plaque Psoriasis
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
This study consists of three parts: single oral dose escalation in healthy volunteers (Part A), and multiple oral dose escalations in healthy volunteers (Part B) and in participants with chronic plaque psoriasis (Part C)
Interventions
Name:
PRCL-02
Type:
DRUG
Description:
Oral tablet(s) administered with water
Name:
Placebo Oral Tablet
Type:
DRUG
Description:
Administered with water
Primary Outcomes
Measure:
Number of Participants with One or More Serious Adverse Events (Part A)
TimeFrame:
Baseline up to approximately 45 days
Description:
Number of participants with a serious adverse event, regardless of causality, by dose and treatment
Measure:
Number of Participants with One or More Serious Adverse Events (Part B)
TimeFrame:
Baseline up to approximately 50 days
Description:
Number of participants with a serious adverse event, regardless of causality, by dose and treatment
Measure:
Number of Participants with One or More Serious Adverse Events (Part C)
TimeFrame:
Baseline up to approximately 73 days
Description:
Number of participants with a serious adverse event, regardless of causality, by dose and treatment
Trial Information
NCT ID
NCT03062618
Status
Completed
Study Type
INTERVENTIONAL
Phases
PHASE1
Sponsor
PRCL Research Inc.
Last Updated
December 15, 2025